A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Condition:   Chickenpox Interventions:   Biological: Investigational varicella vaccine low potency;   Biological: Investigational varicella vaccine medium potency;   Biological: Investigational varicella vaccine high potency;   Biological: Marketed varicella vaccine Lot 1;   Biological: Marketed varicella vaccine Lot 2;   Biological: Measles, mumps, and rubella vaccine;   Biological: Hepatitis A vaccine;   Biological: 13-valent pneumococcal conjugate vaccine Sponsors:   GlaxoSmithKline;   IQVIA, USA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials